BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Target Hit|| Long (1Y)
BoAML maintains buy on Aurobindo Pharma
Duloxetine could be better-than-expected opportunity and may generate over $40 million in first six months. Earnings momentum is expected to remain strong.